Revenue
2018
2019
2020
2021
2022
2023
2024
2025
X4 Pharmaceuticals, Inc (XFOR)
Price$4.04Cached quote
Net income
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.1M | $2.6M | $0 | $0 | $0 | $3.0M | $0 | $0 | — | — |
| Gross profit | $29.4M | $1.8M | $0 | $0 | — | — | — | — | — | — |
| Gross margin | 83.60% | 68.83% | — | — | — | — | — | — | — | — |
| Research & development | $72.7M | $81.6M | $72.0M | $61.1M | $50.6M | $41.9M | $30.2M | $20.3M | $17.1M | $17.8M |
| Operating expenses | $116.2M | $39.0M | $107.5M | $87.6M | $85.1M | $62.9M | $51.7M | $29.1M | $22.2M | $24.3M |
| Operating income | −$86.9M | −$36.4M | −$107.5M | −$87.6M | −$85.1M | −$59.9M | −$51.7M | −$29.1M | −$22.2M | −$24.3M |
| Operating margin | −247.44% | −1,423.58% | — | — | — | −1,995.80% | — | — | — | — |
| EBITDA | −$85.6M | −$35.6M | −$107.1M | −$87.1M | −$84.6M | −$59.5M | −$51.6M | −$29.0M | −$22.2M | −$24.1M |
| EBITDA margin | −243.80% | −1,392.45% | — | — | — | −1,984.10% | — | — | — | — |
| Net income | −$79.2M | −$37.5M | −$101.2M | −$93.9M | −$88.7M | −$62.1M | −$52.8M | −$33.3M | −$22.0M | −$23.0M |
| Net profit margin | −225.55% | −1,464.61% | — | — | — | −2,071.03% | — | — | — | — |
| Basic EPSper basic share | -$1.87 | -$5.59 | -$17.07 | -$45.65 | -$119.82 | -$92.79 | -$139.04 | -$2,376.88 | -$1,639.04 | -$8,068.66 |
| Diluted EPSper diluted share | -$1.87 | -$5.59 | -$17.07 | -$45.65 | -$119.82 | -$92.79 | -$139.04 | -$2,376.88 | -$1,639.04 | -$8,068.66 |
Owners
Reported shareholders
9.84%of listed shares
MORGAN STANLEY9.46M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
MORGAN STANLEY | 9.84%9.46M shares |
FMR LLC | 8.66%8.32M shares |
Bain Capital Life Sciences Investors, LLC | 8.29%7.97M shares |
PERCEPTIVE ADVISORS LLC | 8.25%7.93M shares |
Kalehua Capital Management LLC | 7.75%7.45M shares |
Saturn V Capital Management LP | 7.26%6.97M shares |
Empery Asset Management, LP | 7.21%6.93M shares |
Deep Track Capital, LP | 6.12%5.88M shares |
BlackRock, Inc. | 5.78%5.55M shares |
Nantahala Capital Management, LLC | 5.10%4.9M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.87%3.72M shares |
Ragan Paula | ≈3.47%3.34M shares |
Rosalind Advisors, Inc. | 3.34%3.21M shares |
BRAIDWELL LP | 3.04%2.92M shares |
Blackstone Inc. | 2.79%2.68M shares |
Trails Edge Capital Partners, LP | 2.68%2.57M shares |
BVF INC/IL | 2.32%2.23M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.18%2.1M shares |
Venrock Adviser, LLC | 2.01%1.93M shares |
SAMSARA BIOCAPITAL, LLC | 1.45%1.4M shares |
Percentages use 96.11M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Reported positions exceed 100% in total, so the circle shows the selected holder only.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 12, 2026Form 4 | KIRSKE DAVIDChief Financial Officer | SellCommon Stock | 17.0K | $4.29 | $72.8K | 176.3K |
| Oct 23, 2025Form 4 | Craig Adam RExecutive Chairman | BuyCommon Stock | 86.2K | $2.90 | $250.0K | 376.1K |
| May 16, 2025Form 4 | Baldry MarkChief Commercial Officer | BuyCommon Stock | 1.0K | $2.48 | $2.6K | 25.3K |
| Jan 24, 2025Form 4 | Ragan PaulaPresident and CEO | SellCommon Stock | 76.5K | $0.45 | $34.4K | 1.09M |
| Jan 24, 2025Form 4 | Mostafa Adam S.Chief Financial Officer | SellCommon Stock | 74.8K | $0.45 | $33.6K | 0 |